Advertisement

Tumor Biology

, Volume 35, Issue 8, pp 7935–7944 | Cite as

A new tumor suppressor LncRNA ADAMTS9-AS2 is regulated by DNMT1 and inhibits migration of glioma cells

  • Jie Yao
  • Baosheng Zhou
  • Jian Zhang
  • Peiliang Geng
  • Kang Liu
  • Yunfeng Zhu
  • Weijie Zhu
Research Article

Abstract

Growing number of long noncoding RNAs (lncRNAs) are emerging as new modulators in cancer origination and progression. A lncRNA, ADAM metallopeptidase with thrombospondin type 1 motif, 9 (ADAMTS9) antisense RNA 2 (ADAMTS9-AS2), with unknown function, is the antisense transcript of tumor suppressor ADAMTS9. In the present study, we investigated the expression pattern and functional role of ADAMTS9-AS2 in glioma by using real-time PCR and gain-/loss-of-function studies. The results showed that the ADAMTS9-AS2 expression was significantly downregulated in tumor tissues compared with normal tissues and reversely associated with tumor grade and prognosis. Multivariate analysis of the prognosis factors showed that low ADAMTS9-AS2 expression was a significant independent predictor of poor survival in glioma. Overexpression of ADAMTS9-AS2 resulted in significant inhibition of cell migration in glioma, whereas knockdown of ADAMTS9-AS2 showed the opposite effect. We also found that ADAMTS9-AS2 expression was negatively correlated with DNA methyltransferase-1 (DNMT1). In addition, DNMT1 knockdown led to remarkable enhancement of ADAMTS9-AS2 expression. By 5-aza-dC treatment, the ADAMTS9-AS2 expression was also reactivated. The results suggested that ADAMTS9-AS2 is a novel tumor suppressor modulated by DNMT1 in glioma. LncRNA ADAMTS9-AS2 may serve as a potential biomarker and therapeutic target for glioma.

Keywords

LncRNA ADAMTS9-AS2 Migration Glioma cells 

Notes

Conflicts of interest

None

References

  1. 1.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classifcation of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN. Malignant glioma: genetics and biology of a grave matter. Gene Dev. 2001;15:1311–33.PubMedCrossRefGoogle Scholar
  3. 3.
    Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458:223–7.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Lee JT. Epigenetic regulation by long noncoding RNAs. Science. 2012;338:1435–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Nagano T, Fraser P. No-nonsense functions for long noncoding RNAs. Cell. 2011;145:178–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Huarte M, Rinn JL. Large non-coding RNAs: missing links in cancer? Hum Mol Genet. 2010;19:152–61.CrossRefGoogle Scholar
  7. 7.
    Spizzo R, Almeida MI, Colombatti A, Calin GA. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene. 2012;31:4577–87.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Tsai MC, Spitale RC, Chang HY. Long. Intergenic noncoding RNAs: new links in cancer progression. Cancer Res. 2011;71:3–7.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Pasmant E, Laurendeau I, Heron D, Vidaud M, Vidaud D, Bieche I. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res. 2007;67:3963–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Yu W, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, Feinberg AP, et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature. 2008;451:202–6.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Takayama K, Horie-Inoue K, Katayama S, Suzuki T, Tsutsumi S, Ikeda K, et al. Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO J. 2013;32:1665–80.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Yang X, Song JH, Cheng YL, Wu WJ, Bhagat T, and Yu YT. Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells. Gut .2013;0:1–10.Google Scholar
  13. 13.
    Han L, Kong R, Yin DD, Zhang EB, Xu TP, De W, et al. Low expression of long noncoding RNA GAS6-AS1 predicts a poor prognosis in patients with NSCLC. Med Oncol. 2013;30:694.PubMedCrossRefGoogle Scholar
  14. 14.
    Clark ME, Kelner GS, Turbeville LA, Boyer A, Arden KC, Maki RA. ADAMTS9, a novel member of the ADAM-TS/ metallospondin gene family. Genomics. 2000;67(3):343–50.PubMedCrossRefGoogle Scholar
  15. 15.
    DEMIRCAN K, GUNDUZ E, GUNDUZ M, BEDER LB, HIROHATA S, NAGATSUKA H, et al. Increased mRNA expression of ADAMTS metalloproteinases in metastatic foci of head and neck cancer. Head Neck. 2009;31:793–801.PubMedCrossRefGoogle Scholar
  16. 16.
    Lo PH, Leung AC, Kwok CY, Cheung WS, Ko JM, Yang LC, et al. Identification of a tumor suppressive critical region mapping to 3p14.2 in esophageal squamous cell carcinoma and studies of a candidate tumor suppressor gene, ADAMTS9. Oncogene. 2007;26(1):148–57.PubMedCrossRefGoogle Scholar
  17. 17.
    Lung HL, Lo PH, Xie D, Apte SS, Cheung AK, Cheng Y, et al. Stanbridge and M. L. Lung: Characterization of a novel epigenetically-silenced, growth-suppressive gene, ADAMTS9, and its association with lymph node metastases in nasopharyngeal carcinoma. Int J Cancer. 2008;123(2):401–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Sheu JJ, Lee CH, Ko JY, Tsao GS, Wu CC, Fang CY, et al. Chromosome 3p12.3-p14.2 and 3q26.2–q26.32 are genomic markers for prognosis of advanced nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2009;18(10):2709–16.PubMedCrossRefGoogle Scholar
  19. 19.
    OCAK Z, ACAR M, GUNDUZ E, GUNDUZ M, DEMIRCAN K, UYETURK U, et al. Effect of hypericin on the ADAMTS-9 and ADAMTS-8 gene expression in MCF7 breast cancer cells. Eur Rev Med Pharmacol Sci. 2013;17:1185–90.PubMedGoogle Scholar
  20. 20.
    Du W, Wang S, Zhou Q, Li X, Chu J, Chang Z, et al. ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer. Oncogene. 2013;32:3319–28.PubMedCrossRefGoogle Scholar
  21. 21.
    Viapiano MS, Hockfield S, Matthews RT. BEHAB/brevican requires ADAMTS-mediated proteolytic leavage to promote glioma invasion. J Neurooncol. 2008;88:261–72.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Zhao ZJ, Wu QX, Cheng J, Qiu XM, Zhang JQ, Fan H. Depletion of DNMT3A suppressed cell proliferation and restored PTEN in hepatocellular carcinoma cell. J Biomed Biotechnol. 2010;2010:737535.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Lee J, Jang SJ, Benoit N, Hoque MO, Califano JA, Barry T, et al. Presence of 5-methylcytosine in CpNpG trinucleotides in the human genome. Genomics. 2010;96:67–72.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Han L, Zhang KL, Shi ZD, Zhang JX, Zhu JL, Zhu SJ, et al. LncRNA profile of glioblastoma reveals the potential role of LncRNAs in contributing to glioblastoma pathogenesis. Int J Oncol. 2012;40(6):2004–12.PubMedGoogle Scholar
  25. 25.
    Li R, Qian J, Wang YY, Zhang JX, YP Y, et al. Long noncoding RNA profiles reveal three molecular subtypes in glioma. CNS Neurosci Ther. 2014;2014:1–5.Google Scholar
  26. 26.
    Zhang XQ, Sun S, JK Pu ACT, Lee D, Man VY, et al. Long non-coding RNA expression profiles predict clinical phenotypes in glioma. Neurobiol Dis. 2012;48:1–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Zhang XQ, Sun S, Lam KF, Kiang KY, Pu JK, Ho AS, et al. A long non-coding RNA signature in glioblastoma multiforme predicts survival. Neurobiol Dis. 2013;58:123–31.PubMedCrossRefGoogle Scholar
  28. 28.
    JX Zhang LH, Bao ZS, Wang YY, Chen LY, Yan W, et al. HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma. Neuro-Oncology. 2013;15(12):1595–603.CrossRefGoogle Scholar
  29. 29.
    Shi Y, Wang Y, Luan W, Wang P, Tao T, Zhang J, et al. Long non-coding RNA H19 promotes glioma cell Invasion by deriving miR-675. PLoS ONE. 2014;9:e86295.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Wang PJ, Ren ZQ, Sun PY. Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation. J Cell Biochem. 2012;113(6):1868–74.PubMedCrossRefGoogle Scholar
  31. 31.
    Wahlestedt C. Natural antisense and noncoding RNA transcripts as potential drug targets. Drug Discov Today. 2006;11:503–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Faghihi MA, Wahlestedt C. Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell Biol. 2009;1:637–43.CrossRefGoogle Scholar
  33. 33.
    Yelin R, Dahary D, Sorek R, Levanon EY, Goldstein O, Shoshan A, et al. Widespread occurrence of antisense transcription in the human genome. Nat Biotechnol. 2003;21:379–86.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Cancer CenterChinese PLA General Hospital and Chinese PLA Medical SchoolBeijingChina
  2. 2.Department of OncologyThe 161th Hospital of PLAWuhanChina
  3. 3.Department of NeurosurgeryThe First Central Hospital of TianjinTianjinChina
  4. 4.Department of PathologyPeople’s Hospital of BinzhouBinzhouChina
  5. 5.Neurosurgery DepartmentChinese PLA General HospitalJinanChina
  6. 6.Department of Critical Care MedicineChinese PLA General HospitalBeijingChina

Personalised recommendations